Despite lack of statistical significance in both of these trials for patients with unmethylated tumors, there was a clinical benefit with CRT, which raised the question of whether TMZ should be administered to all GBM patients regardless of MGMT promoter methylation status. Here, MGMT is linked to glioblastoma.